Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction
about
Managing dyslipidemia in HIV/AIDS patients: challenges and solutionsHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsGold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus.Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitorsAvailability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort.The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.HIV-associated lipodystrophy: a review from a Brazilian perspectiveThe development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settingsKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyImpact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders.Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women.Treatment of HIV-Infected Subjects with Buttock Lipoatrophy Using Stabilized Hyaluronic Acid Gel.Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients.People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?Lipodystrophy among patients with HIV infection on antiretroviral therapy: a systematic review protocol.Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox.An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes.Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.CD4+ Cell infiltration into subcutaneous adipose tissue is not indicative of productively infected cells during acute SHIV infection.Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionA Direct Comparison of the Effects of the Antiretroviral Drugs Stavudine, Tenofovir and the Combination Lopinavir/Ritonavir on Bone Metabolism in a Rat Model.What Can We Learn from Interventions That Change Fat Distribution?Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIVStructural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV.Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.Higher Levels of CYSTATIN C in HIV/AIDS Patients with Metabolic Syndrome.Low expression of IL-18 and IL-18 receptor in human skeletal muscle is associated with systemic and intramuscular lipid metabolism-Role of HIV lipodystrophy.Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.Adult antiretroviral therapy guidelines 2017.Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988-2013.Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study
P2860
Q28084941-D6C66E5D-DD04-4497-B5B3-55B404F66DDAQ28088839-4E4D6C57-899D-4858-B802-30334596ED5BQ30394178-4C32F1F5-662E-41DA-98A0-9062F37BFB20Q30625328-FAE8D938-8D10-434C-8F3B-C2BFD3C6EF66Q30795747-40FAD5D4-45EF-4B41-94DE-87B3C05F9621Q33705883-90B2DEF0-9AAF-4D3F-894A-F9406AC7C4E6Q33939681-33C9EE09-45BA-44EE-AD6C-36DC8332593CQ34067682-555DB188-F73D-4C7A-B35C-571589DCD0E6Q34536677-CCBE2564-CD02-440F-8AAD-DDCF6B286FDCQ35134488-95EF890F-C870-40A3-9DBF-9DF8FF7C7296Q35205900-5EB1FCB7-D653-44D4-97AD-1411828C024BQ35567828-2CDB1BFD-79C1-47AD-9E35-5363CD43989DQ35762427-D5A1003D-A5FB-4C57-9873-791D79B66CD5Q35920952-C63901F1-B4AD-4200-A531-50765B847CF3Q35924584-639622FB-E024-431B-930C-E2C6CEA5C92FQ35960732-DA02878E-233F-4E49-885C-E8281F410994Q36249550-9451D8E6-4B81-4A13-982E-4ACDD39812ABQ36426953-FB8D9274-C633-4405-97B7-CE6670B18C6AQ37642995-BD1D7054-FCB2-4518-8CAC-D7BB48DE3F3CQ37657356-0D9A907B-1E07-414F-826F-97B52DC68D25Q37678834-17913E3F-F23A-4D7F-9B5F-CB3F40CDCEE8Q38220651-24AA3559-5FC9-4BD4-9DA5-9A2D7563E0BAQ38614025-C9A8D133-1BBD-40F9-99C5-AFC5F3F5D6CFQ38658293-FFE83893-2B1D-4E03-9342-44B7F66148D1Q38687132-E4208F4C-70EE-40E6-82FF-F9BD42D341FDQ38749963-0CBCB221-7EA4-4353-8F51-F37D78AAB1B6Q38772820-DD3A7282-3548-4E51-A2EA-D08B9CC83290Q38801156-87FAE116-AB1A-4DA9-8F4D-2922B041B6F9Q38821848-7E901862-61AD-470A-AE3C-1EB3C25730DDQ38975330-DF65FEA7-9D06-4778-BE77-0AC90D43A683Q40379251-865FCF21-84C8-40E7-8918-2BB3A79F68A0Q40503132-D275F5BA-A541-48C8-9AD7-B85B104E81A4Q41986511-51786347-C51D-4281-8F1C-870982683E46Q48226767-EDA4D0FE-647F-417F-ADA0-E9B3B89D7587Q50054188-009BE7DE-9529-4BC1-BB88-7D0A18B28A9AQ52641448-8C0412BD-E5AA-4609-9F01-4D3CABC41762Q55095901-5D2B342E-16B8-409C-B45F-F206A9FFA752Q58798902-0C47E4C6-DDEB-4BC7-9E85-5B9B8CD7B04D
P2860
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Systematic review of antiretro ...... troviral adverse drug reaction
@ast
Systematic review of antiretro ...... troviral adverse drug reaction
@en
Systematic review of antiretro ...... troviral adverse drug reaction
@nl
type
label
Systematic review of antiretro ...... troviral adverse drug reaction
@ast
Systematic review of antiretro ...... troviral adverse drug reaction
@en
Systematic review of antiretro ...... troviral adverse drug reaction
@nl
prefLabel
Systematic review of antiretro ...... troviral adverse drug reaction
@ast
Systematic review of antiretro ...... troviral adverse drug reaction
@en
Systematic review of antiretro ...... troviral adverse drug reaction
@nl
P2860
P31
P921
P1433
P1476
Systematic review of antiretro ...... troviral adverse drug reaction
@en
P2093
Reneé de Waal
P2860
P304
P356
10.1371/JOURNAL.PONE.0063623
P407
P5008
P577
2013-05-28T00:00:00Z